Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Menadione Sulfurous Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 1.00 |
| ▸ | PKLR known ✓ | P30613 | 2/20 | 0.34 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | PARG | Q86W56 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Menadione Sulfurous Acid SCHEMBL460403 | 1.00 | MEN1 (1.00) | MEN1KMT2APOLBPARGPKLR | |
| Menadione Sulfurous Acid SCHEMBL29364956 | 1.00 | MEN1 (1.00) | MEN1KMT2APOLBPARGPKLR | |
| Menadione Sulfurous Acid SCHEMBL435171 | 0.98 | MEN1 (0.97) | MEN1KMT2APOLBPARGPKLR | |
| Menadione Sulfurous Acid SCHEMBL29973176 | 0.98 | MEN1 (0.97) | MEN1KMT2APOLBPARGPKLR | |
| Menadione Sulfurous Acid SCHEMBL459906 | 0.95 | MEN1 (0.91) | MEN1KMT2APOLBPARGPKLR | |
| Menadione Sulfurous Acid SCHEMBL461201 | 0.95 | MEN1 (0.91) | MEN1KMT2APOLBPARGPKLR | |
| SCHEMBL18309831 | 0.81 | MEN1 (0.69) | MEN1KMT2APOLBPARGALDH1A1 | |
| Menadione Sulfurous Acid SCHEMBL461613 | 0.81 | POLB (0.68) | MEN1KMT2APOLBPARGALDH1A1 | |
| Menadione Sulfurous Acid SCHEMBL460404 | 0.81 | POLB (0.68) | MEN1KMT2APOLBPARGALDH1A1 | |
| Menadione Sulfurous Acid SCHEMBL459525 | 0.80 | POLB (0.67) | MEN1KMT2APOLBPARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12295957-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | IC-MedTech Corp. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20240398755-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE | IC-MedTech Corp. | 2024-12-05 | — | — | US | disclosed |
| US-11998523-B2 | Ascorbic acid and quinone compounds for treating Chagas disease | IC-MedTech Corp. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240165084-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE | IC-MedTech Corp. | 2024-05-23 | — | — | US | disclosed |
| US-11872233-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | IC-MedTech Corp. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20220409577-A1 | INTRATUMORAL ADMINISTRATION OF ASCORBIC ACID AND QUINONE COMPOUNDS FOR TUMOR TREATMENT | IC-MedTech Corp. | 2022-12-29 | — | — | US | disclosed |
| US-20210361666-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE | MARINGA STATE UNIVERSITY (BR) | 2021-11-25 | — | — | US | disclosed |
| US-20210283100-A1 | ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER | IC MEDTECH CORP (US) | 2021-09-16 | — | — | US | disclosed |
| US-20190343794-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE | IC-MedTech Corp. | 2019-11-14 | — | — | US | disclosed |
| EP-3490543-A1 | ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER | IC-Medtech Corp. (US) | 2019-06-05 | — | — | EP | disclosed |
| US-9050265-B2 | Vitamin C and vitamin K, and compositions thereof for treatment of osteolysis or prolongation of prosthetic implant | SUMMA HEALTH SYSTEM (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140200270-A1 | VITAMINS C AND K FOR TREATING POLYCYSTIC DISEASES | SUMMA HEALTH SYSTEM (US) | 2014-07-17 | — | — | US | disclosed |
| WO-2014110305-A1 | VITAMINS C AND K FOR TREATING POLYCYSTIC DISEASES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014074765-A2 | VITAMIN C, VITAMIN K, A POLYPHENOL, AND COMBINATIONS THEREOF FOR WOUND HEALING | SUMMA HEALTH SYSTEM (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20130178522-A1 | VITAMIN C AND CHROMIUM-FREE VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATING AN NFKB-MEDIATED CONDITION OR DISEASE | SUMMA HEALTH SYSTEM | 2013-07-11 | — | — | US | disclosed |
| EP-2595615-A1 | VITAMIN C AND CHROMIUM-FREE VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATING AN NFKB-MEDIATED CONDITION OR DISEASE | Summa Health System (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20120184609-A1 | VITAMIN C AND VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATMENT OF OSTEOLYSIS OR PROLONGATION OF PROSTHETIC IMPLANT | SUMMA HEALTH SYSTEM (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2456306-A1 | VITAMIN C AND VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATMENT OF OSTEOLYSIS OR PROLONGATION OF PROSTHETIC IMPLANT | Summa Health System (US) | 2012-05-30 | — | — | EP | disclosed |
| WO-2012012370-A1 | VITAMIN C AND CHROMIUM-FREE VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATING AN NFKB-MEDIATED CONDITION OR DISEASE | SUMMA HEALTH SYSTEM (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2011011317-A1 | VITAMIN C AND VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATMENT OF OSTEOLYSIS OR PROLONGATION OF PROSTHETIC IMPLANT | SUMMA HEALTH SYSTEM (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283100-A1 | ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER | SLC5A1, SLC5A2, SLC5A6 | MEN1 937/4885PKLR 2901/4885THRB 3414/4885 |
| US-11872233-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | NQO1, ADH7, CYP27B1 | MEN1 2407/4885PKLR 3100/4885THRB 3967/4885 |
| US-20210361666-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE | NQO1, ADH7, CYP27B1 | MEN1 2407/4885PKLR 3100/4885THRB 3967/4885 |
| US-20220409577-A1 | INTRATUMORAL ADMINISTRATION OF ASCORBIC ACID AND QUINONE COMPOUNDS FOR TUMOR TREATMENT | NDUFB7, NDUFA12, NDUFB11 | MEN1 1050/4885PKLR 3555/4885THRB 2730/4885 |
| US-20240165084-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE | NQO1, ADH7, CYP27B1 | MEN1 2407/4885PKLR 3100/4885THRB 3967/4885 |
| US-11998523-B2 | Ascorbic acid and quinone compounds for treating Chagas disease | NQO1, ADH7, TALDO1 | MEN1 2264/4885PKLR 2697/4885THRB 3280/4885 |
| US-20130178522-A1 | VITAMIN C AND CHROMIUM-FREE VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATING AN NFKB-MEDIATED CONDITION OR DISEASE | PROC, NFKB2, NFKBIA | MEN1 1839/4885PKLR 620/4885THRB 2863/4885 |
| US-12295957-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | NQO1, ADH7, CYP27B1 | MEN1 2407/4885PKLR 3100/4885THRB 3967/4885 |
| US-20190343794-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE | NQO1, ADH7, TALDO1 | MEN1 2264/4885PKLR 2697/4885THRB 3280/4885 |
| US-20120184609-A1 | VITAMIN C AND VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATMENT OF OSTEOLYSIS OR PROLONGATION OF PROSTHETIC IMPLANT | PROC, VKORC1, VKORC1L1 | MEN1 2175/4885PKLR 1250/4885THRB 2402/4885 |
| US-20240398755-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE | NQO1, ADH7, TALDO1 | MEN1 2264/4885PKLR 2697/4885THRB 3280/4885 |
| US-20140200270-A1 | VITAMINS C AND K FOR TREATING POLYCYSTIC DISEASES | PROC, PKD1, VKORC1L1 | MEN1 527/4885PKLR 78/4885THRB 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.